Fig. 1 | Modern Pathology

Fig. 1

From: Reappraisal of HER2 status in the spectrum of advanced urothelial carcinoma: a need of guidelines for treatment eligibility

Fig. 1

Flowchart showing the three-step approach for HER2 assessment in our cohort of locally advanced urothelial carcinoma of the bladder. * Eligible cases to FISH in our study: moderate or strong, complete or incomplete HER2 membrane staining in ≥10% of tumor cells. ASCO/CAP American Society of Clinical Oncology/College of American Pathologists, FISH fluorescent in situ hybridization, HER2 human epidermal growth factor receptor 2, LN lymph node metastases, T primary tumor

Back to article page